deferoxamine has been researched along with Cardiac Death in 3 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cardiac events and death are not uncommon in adults with beta-thalassemia (b-TM) taking deferoxamine (DFO) monotherapy because of poor compliance and possibly the less effectiveness of DFO in controlling cardiac iron overload." | 7.76 | Cardiac events and cardiac T2* in Egyptian children and young adults with beta-thalassemia major taking deferoxamine. ( Abdin, IA; Ebeid, FS; El Safy, UR; Elalfy, MS; Ibrahim, AS; Salem, DS, 2010) |
| "Cardiac events and death are not uncommon in adults with beta-thalassemia (b-TM) taking deferoxamine (DFO) monotherapy because of poor compliance and possibly the less effectiveness of DFO in controlling cardiac iron overload." | 3.76 | Cardiac events and cardiac T2* in Egyptian children and young adults with beta-thalassemia major taking deferoxamine. ( Abdin, IA; Ebeid, FS; El Safy, UR; Elalfy, MS; Ibrahim, AS; Salem, DS, 2010) |
| "The risk of cardiac death during 1990-1999 and 2000-2008 was compared." | 1.36 | Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit. ( Berdoukas, V; Berdoussi, E; Chouliaras, G; Kattamis, C; Ladis, V; Moraitis, P; Zannikos, K, 2010) |
| "The incidence of cardiac death in both groups was analyzed." | 1.33 | Survival in thalassaemia major patients. ( Efthimiadis, GK; Giannakoulas, GA; Hassapopoulou, HP; Karvounis, HI; Louridas, GE; Parharidis, GE; Tsikaderis, DD, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ladis, V | 1 |
| Chouliaras, G | 1 |
| Berdoukas, V | 1 |
| Moraitis, P | 1 |
| Zannikos, K | 1 |
| Berdoussi, E | 1 |
| Kattamis, C | 1 |
| Elalfy, MS | 1 |
| Abdin, IA | 1 |
| El Safy, UR | 1 |
| Ibrahim, AS | 1 |
| Ebeid, FS | 1 |
| Salem, DS | 1 |
| Efthimiadis, GK | 1 |
| Hassapopoulou, HP | 1 |
| Tsikaderis, DD | 1 |
| Karvounis, HI | 1 |
| Giannakoulas, GA | 1 |
| Parharidis, GE | 1 |
| Louridas, GE | 1 |
3 other studies available for deferoxamine and Cardiac Death
| Article | Year |
|---|---|
Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit.
Topics: Adolescent; Adult; Age Factors; Benzoates; beta-Thalassemia; Child; Death; Deferasirox; Deferiprone; | 2010 |
Cardiac events and cardiac T2* in Egyptian children and young adults with beta-thalassemia major taking deferoxamine.
Topics: Adolescent; Age Factors; Benzoates; beta-Thalassemia; Child; Child, Preschool; Death; Deferasirox; D | 2010 |
Survival in thalassaemia major patients.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Death; Deferoxamine; Echocardiography, Doppl | 2006 |